tetano
Editor, Senior Moderator
J Infect Dis. 2015 Apr 8. pii: jiv195. [Epub ahead of print]
[h=1]Antibody to the influenza neuraminidase: an independent correlate of protection.[/h] Monto AS[SUP]1[/SUP], Petrie JG[SUP]1[/SUP], Cross RT[SUP]1[/SUP], Johnson E[SUP]1[/SUP], Liu M[SUP]2[/SUP], Zhong W[SUP]2[/SUP], Levine M[SUP]2[/SUP], Katz JM[SUP]2[/SUP], Ohmit SE[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Laboratory correlates of influenza vaccine protection can best be identified by examining those who fail vaccination. While the importance of antibody to viral hemagglutinin (HA) has long been recognized, the independent contribution to protection of antibody to viral neuraminidase (NA) has not been determined.
[h=4]METHODS:[/h] Sera from a controlled trial of inactivated (IIV) and live attenuated (LAIV) influenza vaccine efficacy were tested by hemagglutination inhibition (HAI), microneutralization (MN) and a newly standardized lectin-based neuraminidase inhibition (NAI) assay.
[h=4]RESULTS:[/h] Vaccine response measured by NAI was found in 37% of IIV recipients, as compared to 77% and 67% by HAI and MN, respectively. For LAIV, the percentages were 6%, 21% and 17%, respectively. In IIV recipients, as NAI titers rose, the frequency of vaccine failure fell, similar to that seen with HAI and MN. HAI and MN titers were highly correlated, but NAI titers less so. Analyses suggested an independent role for NAI antibody in protection which was similar in IIV, LAIV and placebo groups.
[h=4]CONCLUSION:[/h] While NAI antibody is not produced to a large extent in response to current IIV, it appears to have an independent role in protection. As new influenza vaccines are developed, NA content should be considered.
? The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
PMID: 25858957 [PubMed - as supplied by publisher]
[h=1]Antibody to the influenza neuraminidase: an independent correlate of protection.[/h] Monto AS[SUP]1[/SUP], Petrie JG[SUP]1[/SUP], Cross RT[SUP]1[/SUP], Johnson E[SUP]1[/SUP], Liu M[SUP]2[/SUP], Zhong W[SUP]2[/SUP], Levine M[SUP]2[/SUP], Katz JM[SUP]2[/SUP], Ohmit SE[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Laboratory correlates of influenza vaccine protection can best be identified by examining those who fail vaccination. While the importance of antibody to viral hemagglutinin (HA) has long been recognized, the independent contribution to protection of antibody to viral neuraminidase (NA) has not been determined.
[h=4]METHODS:[/h] Sera from a controlled trial of inactivated (IIV) and live attenuated (LAIV) influenza vaccine efficacy were tested by hemagglutination inhibition (HAI), microneutralization (MN) and a newly standardized lectin-based neuraminidase inhibition (NAI) assay.
[h=4]RESULTS:[/h] Vaccine response measured by NAI was found in 37% of IIV recipients, as compared to 77% and 67% by HAI and MN, respectively. For LAIV, the percentages were 6%, 21% and 17%, respectively. In IIV recipients, as NAI titers rose, the frequency of vaccine failure fell, similar to that seen with HAI and MN. HAI and MN titers were highly correlated, but NAI titers less so. Analyses suggested an independent role for NAI antibody in protection which was similar in IIV, LAIV and placebo groups.
[h=4]CONCLUSION:[/h] While NAI antibody is not produced to a large extent in response to current IIV, it appears to have an independent role in protection. As new influenza vaccines are developed, NA content should be considered.
? The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
PMID: 25858957 [PubMed - as supplied by publisher]